Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE frowns on Botox for headache prevention

February 16, 2012
Sales and Marketing Allergan, Botox, EMA, NHS, NICE

NICE is not recommending Allergan’s Botox for headache prevention, and has asked the firm for more information on the drug.  …

News

Emerging markets no haven from HTA, says NICE

February 15, 2012
Andrew Witty, GSK, NICE, NICE International

The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …

News
Herceptin and Tyverb image

NICE cannot recommend breast cancer drugs

February 14, 2012
Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb

NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …

News

New drug discounts should be made transparent

February 8, 2012
Medical Communications, Sales and Marketing ABPI, NHS, NICE, access scheme, pricing

Patient access schemes agreed through NICE should be made more transparent.  This is according to Paul McManus, a pharmacist and …

News
Zytiga image

Zytiga cost too high, says NICE

February 2, 2012
Sales and Marketing NICE, Zytiga

NICE is not recommending Janssen’s prostate cancer pill Zytiga because of its high cost. Zytiga (abiraterone) is not recommended, in …

News

The work of NICE International

January 17, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kalipso Chalkidou, NICE

NICE, or the National Institute for Health and Clinical Excellence, to give it its full title, is world famous for …

Feature
Avastin picture

Avastin now available in UK for ovarian cancer

January 17, 2012
Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin

Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …

News

NICE says yes to Tasigna for resistant disease

January 13, 2012
Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna

NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …

News
NICE picture

NICE rejects Sanofi’s Jevtana

January 12, 2012
Sales and Marketing Jevtana, NICE, Sanofi, Zytiga

NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …

News

NICE guidance to be enforced, says Lansley

January 11, 2012
Sales and Marketing NHS, NICE, PCTs, black lists, prescribing

Local NHS organisations will no longer be allowed to ‘ban’ drugs recommended by NICE, the health secretary has said.England’s primary …

News

NICE set to reject Xarelto in AF

January 10, 2012
Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation

NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …

News
Faslodex picture

NICE rejects AstraZeneca’s breast cancer drug

December 14, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE

NICE has made its final decision not to recommended AstraZeneca’s breast cancer drug Faslodex, as it says the drug is …

News

NICE gains wider public health role

December 7, 2011
Sales and Marketing NICE

NICE is to gain new powers to advise local authorities in England and Wales about public health.From 2013 responsibility for public health will …

News
Gilenya picture

Discount fails to sway NICE on Gilenya

December 1, 2011
Sales and Marketing NICE, Novartis, gilenya

NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …

News
Credit cards picture

NICE wishes you a cost effective Christmas

November 30, 2011
Sales and Marketing NICE

NICE has disclosed information about its use of corporate credit cards following a request made under the Freedom of Information …

Feature
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026